ADRB2 and chronic obstructive pulmonary disease: The study concluded that the preference of BDR for either β2-agonists or anticholinergics in COPD patients may rely on ADRB2 polymorphism, and a possible combination of these two treatments might be more effective than monotherapy with only one drug category [29].